Literature DB >> 28624693

Immune-related eosinophilia induced by anti-programmed death 1 or death-ligand 1 antibodies.

Alice Bernard-Tessier1, Priscilla Jeanville2, Stéphane Champiat1, Julien Lazarovici3, Anne-Laure Voisin2, Christine Mateus4, Olivier Lambotte5, Maxime Annereau2, Jean-Marie Michot6.   

Abstract

Entities:  

Keywords:  Anti-programmed death 1; Anti-programmed death ligand 1; Emergent adverse event; Eosinophilia; Immune-related adverse event

Mesh：

Substances：

Year:  2017        PMID： 28624693     DOI： 10.1016/j.ejca.2017.05.017

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN： 0959-8049            Impact factor:   9.162


× No keyword cloud information.
  20 in total

Review 1.  Eosinophils and Lung Cancer: From Bench to Bedside.

Authors:  Anne Sibille; Jean-Louis Corhay; Renaud Louis; Vincent Ninane; Guy Jerusalem; Bernard Duysinx
Journal:  Int J Mol Sci       Date:  2022-05-03       Impact factor: 6.208

2.  Blood Eosinophils Are Associated with Efficacy of Targeted Therapy in Patients with Advanced Melanoma.

Authors:  Simone Wendlinger; Jonas Wohlfarth; Sophia Kreft; Claudia Siedel; Teresa Kilian; Ulrich Dischinger; Markus V Heppt; Kilian Wistuba-Hamprecht; Friedegund Meier; Matthias Goebeler; Dirk Schadendorf; Anja Gesierich; Corinna Kosnopfel; Bastian Schilling
Journal:  Cancers (Basel)       Date:  2022-05-04       Impact factor: 6.575

Review 3.  Programmed T cell differentiation: Implications for transplantation.

Authors:  Rebecca L Crepeau; Mandy L Ford
Journal:  Cell Immunol       Date:  2020-03-29       Impact factor: 4.868

4.  Hyperprogressive Disease and Early Hypereosinophilia After Anti-PD-1 Treatment: A Case Report.

Authors:  Mario Occhipinti; Rosa Falcone; Concetta Elisa Onesti; Paolo Marchetti
Journal:  Drug Saf Case Rep       Date:  2018-03-13

5.  Predictive and prognostic role of peripheral blood eosinophil count in triple-negative and hormone receptor-negative/HER2-positive breast cancer patients undergoing neoadjuvant treatment.

Authors:  Concetta Elisa Onesti; Claire Josse; Aurélie Poncin; Pierre Frères; Christophe Poulet; Vincent Bours; Guy Jerusalem
Journal:  Oncotarget       Date:  2018-09-14

6.  Dual checkpoint inhibitor-associated eosinophilic enteritis.

Authors:  J Yang; S M Lagana; Y M Saenger; R D Carvajal
Journal:  J Immunother Cancer       Date:  2019-11-15       Impact factor: 13.751

7.  Moderate-to-severe eosinophilia induced by treatment with immune checkpoint inhibitors: 37 cases from a national reference center for hypereosinophilic syndromes and the French pharmacovigilance database.

Authors:  Quentin Scanvion; Johana Béné; Sophie Gautier; Aurélie Grandvuillemin; Christine Le Beller; Chouki Chenaf; Nicolas Etienne; Solenn Brousseau; Alexis B Cortot; Laurent Mortier; Delphine Staumont-Sallé; Franck Morschhauser; Alexandra Forestier; Matthieu Groh; David Launay; Eric Hachulla; Myriam Labalette; Jean-Emmanuel Kahn; Guillaume Lefèvre
Journal:  Oncoimmunology       Date:  2020-04-07       Impact factor: 8.110

8.  Peripheral blood eosinophilia may be a prognostic biomarker in non-small cell lung cancer patients treated with immunotherapy.

Authors:  Adelaide Alves; Margarida Dias; Sérgio Campainha; Ana Barroso
Journal:  J Thorac Dis       Date:  2021-05       Impact factor: 2.895

9.  Targeting the mTOR pathway uncouples the efficacy and toxicity of PD-1 blockade in renal transplantation.

Authors:  Khashayar Esfahani; Tho-Alfakar Al-Aubodah; Pamela Thebault; Réjean Lapointe; Marie Hudson; Nathalie A Johnson; Dana Baran; Najwa Bhulaiga; Tomoko Takano; Jean-François Cailhier; Ciriaco A Piccirillo; Wilson H Miller
Journal:  Nat Commun       Date:  2019-10-17       Impact factor: 14.919

10.  Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events.

Authors:  Julie R Brahmer; Hamzah Abu-Sbeih; Paolo Antonio Ascierto; Jill Brufsky; Laura C Cappelli; Frank B Cortazar; David E Gerber; Lamya Hamad; Eric Hansen; Douglas B Johnson; Mario E Lacouture; Gregory A Masters; Jarushka Naidoo; Michele Nanni; Miguel-Angel Perales; Igor Puzanov; Bianca D Santomasso; Satish P Shanbhag; Rajeev Sharma; Dimitra Skondra; Jeffrey A Sosman; Michelle Turner; Marc S Ernstoff
Journal:  J Immunother Cancer       Date:  2021-06       Impact factor: 13.751
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.